Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Summary not available.
AstraZeneca and Merck (NYSE: MRK) announced an extension to the FDA's Prescription Drug User Fee Act (PDUFA) date by three months for the supplemental new drug application (sNDA) regarding LYNPARZA in combination with abiraterone and prednisone for treating metastatic castration-resistant prostate cancer (mCRPC). The extension aims to allow further review of the application, which is supported by the Phase 3 PROpel trial data. LYNPARZA is already approved for certain indications in the U.S. and EU, with ongoing regulatory reviews in additional countries.
Moderna and Merck announced positive results from the Phase 2b KEYNOTE-942 trial of mRNA-4157/V940 combined with KEYTRUDA in stage III/IV melanoma patients. The study showed a 44% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone. This marks the first efficacy demonstration of an mRNA cancer treatment in a randomized trial. The companies plan to initiate a Phase 3 study and expand to other tumor types in 2023. Adverse events associated with mRNA-4157/V940 were consistent with previous studies, indicating manageable safety.
Merck (NYSE: MRK) has initiated a cash tender offer for all outstanding shares of Imago BioSciences (NASDAQ: IMGO) at $36 per share. This follows a definitive agreement announced on November 21, 2022, to acquire Imago. The tender offer is set to expire on January 10, 2023. Upon successful completion, Imago will merge into a Merck subsidiary and become a wholly-owned entity. The tender offer is subject to conditions, including the tender of a majority of Imago's shares and necessary regulatory approvals. Closing is expected in Q1 2023.
Merck (NYSE: MRK) announced the presentation of new data on investigational drugs, including favezelimab, zilovertamab vedotin, and nemtabrutinib, at the 64th American Society of Hematology (ASH) Annual Meeting from Dec. 10-13, 2022, in New Orleans and virtually. Key findings will involve nearly 40 abstracts showcasing advancements in blood cancer treatments, including new insights on KEYTRUDA (pembrolizumab). Dr. Gregory Lubiniecki emphasized Merck's commitment to enhancing the treatment landscape for blood cancer patients and the importance of their growing pipeline of therapies.
Merck (NYSE: MRK) announced a quarterly dividend of $0.73 per share for Q1 2023, to be paid on Jan. 9, 2023. This payment is for shareholders of record as of Dec. 15, 2022. Merck aims to leverage leading-edge science to improve lives globally and remains committed to research and development in the biopharmaceutical sector. The company emphasizes its dedication to sustainability and a diverse workforce, striving for a healthy future for all communities.
Merck (NYSE: MRK) announced positive topline results from the pivotal Phase 3 KEYNOTE-859 trial, where KEYTRUDA® (pembrolizumab) combined with chemotherapy significantly improved overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. The independent Data Monitoring Committee confirmed these statistically significant findings. No new safety concerns were identified. Results will be presented at future medical meetings and submitted for regulatory review.
Merck's potential approval for LYNPARZA in combination with abiraterone for treating metastatic castration-resistant prostate cancer (mCRPC) has gained a positive opinion from the European Medicines Agency's CHMP. The Phase 3 PROpel trial results showed a 34% reduction in disease progression or death compared to placebo, with median radiographic progression-free survival of 24.8 months. While the safety profile aligns with prior studies, 14% of patients discontinued treatment due to side effects, including anemia and fatigue.
Merck (NYSE: MRK) announced a new systematic literature review published in the Expert Review of Vaccines, detailing the global effectiveness of the GARDASIL vaccine. Covering 138 studies from 23 countries, the review highlights significant reductions in high-grade cervical lesions and HPV infections among vaccinated populations. Key findings include a 73% reduction in CIN3+ lesions in females aged 14-17 and a 96% decrease in vaccine-type HPV infections. The review underscores the necessity of expanding vaccination efforts to combat HPV-related cancers globally.
Veeva Systems (NYSE: VEEV) has announced a ten-year strategic partnership with Merck (NYSE: MRK), building upon their existing 12-year collaboration. The agreement entails Merck adopting a Veeva-first approach for new software and data solutions, aimed at reducing operational costs and enhancing patient and healthcare professional experiences. Veeva will offer a strategic pricing model and seek Merck's input on product development. This partnership is designed to accelerate Merck's digital transformation and improve efficiency in utilizing Veeva’s integrated platform.